無料プレビュー

argenx SE (ARGX) · NASDAQ Global Select

プロフィール

Argenx is a biopharmaceutical company developing and commercializing monoclonal antibody and protein therapeutic products for autoimmune and other rare diseases. The company's marketed product is VYVGART (efgartigimod), approved for generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and immune thrombocytopenia in Japan, with pipeline candidates including empasiprubart and adimanebart for additional indications. Argenx operates a global commercialization infrastructure with distribution partnerships and direct sales operations across the U.S., EU, and other jurisd

主要指標

株価: $818.63 (-11.83%)
時価総額: 509億ドル
PER（今期予想）: 28.4
PBR: 5.8
配当利回り: —
52週レンジ: $661.85 – $1072.75
業種: Healthcare / Biotechnology
上場: NASDAQ Global Select
構成銘柄: —

比較会社: AMGN Amgen Inc.、VRTX Vertex Pharmaceuticals Incorporated、MRNA Moderna, Inc.、REGN Regeneron Pharmaceuticals, Inc.、SGEN Seagen Inc.、RVMD Revolution Medicines, Inc.、ONC BeOne Medicines AG、BIIB Biogen Inc.

長期トレンド・直近動向・強気／弱気シナリオ・業績10年・バリュエーション・テクニカル・株主・役員・深掘り分析は会員向けです。

7日間無料で全文を読むログイン

次回決算: 2027-03-04 · 更新: 2026-10-09